Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
MPS I
Pompe
Disease Information
Management of Pompe Disease
Symptomatic or corrective management
Specific therapies
About Myozyme®
Reconstitution & Administration
Myozyme® clinical trial summary
Summary of Product Characteristics
Medical Information Services
Pompe Registry
Practical Info
Request Materials
Testimonials on the Pompe disease

 



 

Management of Pompe disease

Because of the multisystemic and heterogeneous nature of Pompe disease, patients should receive multidisciplinary attention, including consultation with specialists in this disorder as necessary.

Individual management decisions will largely depend upon a comprehensive and regular evaluation of the severity and progression of the disease in that patient. Early intervention may enhance the benefits of treatment.

Treatment of Pompe disease can be classed as general symptomatic or corrective treatment and therapy specifically targeted at the underlying cause.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with Cerezyme®

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with Fabrazyme® significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease